United States of America ex rel. v. Janssen Biotech, Inc.

District Court, D. Massachusetts·Decided September 9, 2022·No. 1:16-cv-12182·Unknown

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

THE UNTED STATES OF AMERICA et al. ex rel. JULIE LONG, Plaintiffs,

v. CIVIL ACTION NO. 16-12182-FDS

JANSSEN BIOTECH, INC., Defendant.

MEMORANDUM AND ORDER ON RELATOR’S MOTIONS TO COMPEL RESPONSES TO INTERROGATORIES (##278, 306)

KELLEY, U.S.M.J. I. Introduction. This is a qui tam action alleging that a pharmaceutical company unlawfully provided free business advisory services to physicians who prescribed its medications, in violation of the Anti- Kickback Statute, 42 U.S.C. § 1320a-7b(b), and caused physicians to submit false claims for reimbursement to Medicare in violation of the False Claims Act, 31 U.S.C. § 3729(a). Relator Julie Long alleges that Janssen Biotech, a company that manufactures and sells two infusible drugs, Remicade and Simponi ARIA, improperly employed teams of practice advisors, including relator, and hired outside consultants to provide services such as presentations, advice, and customized analyses to doctors to assist them in running profitable infusion businesses. The facts of the case and a detailed analysis of the claims in the Second Amended Complaint (#55) are set out in Chief Judge Saylor’s Order and Memorandum on Defendant’s Motion to Dismiss. (#75.) In addition, this court presumes familiarity with an order this court issued concerning other discovery matters, (#282), which sets out the background concerning discovery in this case in detail. II. Relator’s Pending Motions to Compel. On January 19, 2021, relator issued her first set of interrogatories, which included

Interrogatory No. 15. (#101-3.) Janssen responded with objections (#101-5), and relator then moved to compel a more fulsome response. (#100.) After multiple hearings on the motion, the parties conferred and relator agreed to amend Interrogatory No. 15, which it served to Janssen on May 12, 2021. (#137 at 1.) The court ordered Janssen to respond (#139), and Janssen did so on June 22, 2021. (#279-8.) On January 3, 2022, relator served Janssen with Interrogatory Nos. 20, 21, and 22; Janssen provided answers on February 4, 2022. (#307 at 3.) Relator then filed her first motion to overrule Janssen’s objections and compel complete responses to those interrogatories on February 16, 2022. (#278.) In response, Janssen filed a memorandum outlining its objections to the interrogatories,

indicating that it would supplement its answers regardless, and asking the court to deny the motion to compel as moot. (#294.) Janssen supplemented its answers on March 17, 2022. (#307-2.) Relator filed a renewed motion to compel revised responses to Interrogatory Nos. 20 and 22, and also sought to compel a revised response to Amended Interrogatory No. 15 and revised initial disclosures. (#306.)1

1 Relator’s renewed motion did not request a supplemental response to Interrogatory No. 21. See #306. In light of relator’s renewed motion to compel, relator’s first motion to compel (#278) is DENIED as moot. For the reasons discussed below, relator’s renewed motion to compel (#306) is ALLOWED in part and DENIED in part. III. Discussion. Relator’s renewed motion seeks to compel revised responses to three interrogatories, as

well as revisions to Janssen’s initial disclosures. (#306.) Janssen argues several grounds in opposition (grounds that it also raised in its objections to the interrogatories), including that the interrogatories are untimely, exceed the number allowed, are overbroad, and request information that is privileged. (#309.) In addition, Janssen argues that relator has sufficient information from its responses, combined with documents produced to date, so that revised responses and disclosures are unnecessary. Id. at 9-10, 12. A. Interrogatory Nos. 15 (Amended), 20, and 22. The three requests at issue are contention interrogatories, asking Janssen to identify the facts, documents, witnesses and evidence that support three of its affirmative defenses. Amended

Interrogatory No. 15 asks Janssen to [s]tate all the facts that you believe support your contention in Affirmative Defense No. 13 of your Answer to the Second Amended Complaint that “Janssen reasonably interpreted the statutes and regulations at issue in the SAC,” including identifying all persons who performed the analyses that form the basis for Affirmative Defense No. 13 and when such analyses were performed. (#279-8 at 8.) Interrogatory No. 20 asks Janssen to [s]tate whether you contend that when you provided each of the various types of IOI Support and IOI Support Programs that you had a good faith belief that your actions did not violate any law, statute, or regulation, and if so set forth all facts, documents, and evidence that support your contention and identify the witnesses who have knowledge concerning your contention. (#307-2 at 7.) Finally, Interrogatory No. 22 states, [i]n Affirmative Defense No. 8 of your Answer to the Second Amended Complaint you contend that “any false claims that Janssen allegedly submitted or caused to be submitted and any false record or statement that Janssen allegedly made, used, or caused to be made or used to get a claim paid were not done knowingly.” Set forth all facts, documents, and evidence that support your contention and identify the witnesses who have knowledge concerning your contention. Id. at 14. In both its first and supplemental responses to relator’s Interrogatory Nos. 20 and 22, as well as its responses to relator’s Amended Interrogatory No. 15, Janssen raises several objections to the interrogatories while also providing partial responses to the requests. (#279-8 at 8-10; #307- 2 at 7-11, 14-18.) These objections were also raised in Janssen’s responses to relator’s motions to compel. (##294, 309.) 1. Whether the Requests Were Untimely. On December 14, 2020, Chief Judge Saylor set a schedule for phase one of discovery, which was anticipated to last for three months. (##89, 90.) At that time, December 22, 2020 was the deadline to serve initial disclosures; January 22, 2021 was the deadline to serve written discovery requests; and March 22, 2021 was the deadline for fact depositions. (#89.) He declined to set deadlines for the amendment of pleadings, expert disclosures, or dispositive motions. (#90 at 6:4-6.) On February 5, 2021, Chief Judge Saylor amended the schedule by extending the deadline for fact depositions to April 22, 2021. (#94.) After that, extensions were repeatedly granted, though they extended “fact discovery” generally without reference to a specific type of discovery. See ##106, 134, 156, 197, 211, 243. The most recent amendment indicated that the “discovery deadline” was extended to April 29, 2022. (#287.) Janssen’s position is that the written discovery request deadline remained January 22, 2021, while other deadlines—including their obligation to respond to discovery requests and the deadline for fact depositions—were extended. (#309 at 7.) Having reviewed transcripts from the hearings and status conferences surrounding each discovery extension, the court cannot interpret these extensions as narrowly as Janssen would have it. Janssen is continuing to respond to written document requests and has successfully advocated for this discovery phase to end with summary judgment motions. (#174 (memorandum in support of motion to set schedule, arguing that

Free access — add to your briefcase to read the full text and ask questions with AI

United States of America ex rel. v. Janssen Biotech, Inc., (D. Mass. 2022).

United States of America ex rel. v. Janssen Biotech, Inc. (United States of America ex rel. v. Janssen Biotech, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Scott v. Chipotle Mexican Grill, Inc.
67 F. Supp. 3d 607 (S.D. New York, 2014)
Trevino v. ACB American, Inc.
232 F.R.D. 612 (N.D. California, 2006)